{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:37:10Z","timestamp":1793317030650,"version":"4.5.0"},"reference-count":126,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ctrv.2026.103221","type":"journal-article","created":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:17:39Z","timestamp":1791123459000},"page":"103221","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Molecular tumor boards implementation in Europe: a scoping review and thematic analysis of challenges and facilitators"],"prefix":"10.1016","volume":"150","author":[{"given":"Nicol\u00f2","family":"Lentini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Giacobini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Sabatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Boccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Pastorino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2026.103221_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2024.101250","article-title":"Current and emerging sequencing-based tools for precision cancer medicine","volume":"96","author":"Edsj\u00f6","year":"2024","journal-title":"Mol Asp Med"},{"key":"10.1016\/j.ctrv.2026.103221_bb0010","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/s41571-023-00824-4","article-title":"Molecular tumour boards - current and future considerations for precision oncology","volume":"20","author":"Tsimberidou","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0015","first-page":"23","article-title":"Molecular tumor boards clinical impact on patient care and structural features: a systematic review and meta-analysis","author":"Russo","year":"2026","journal-title":"PLoS Med"},{"key":"10.1016\/j.ctrv.2026.103221_bb0020","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.annonc.2025.02.009","article-title":"ESMO precision oncology working group recommendations on the structure and quality indicators for molecular tumour boards in clinical practice","volume":"36","author":"Westphalen","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16162888","article-title":"Evolving and Improving the Sustainability of Molecular Tumor Boards: The Value and Challenges","volume":"16","author":"Bartels","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ctrv.2026.103221_bb0030","first-page":"41","article-title":"Bridging therapeutic opportunities: a survey by the Italian molecular tumor board workgroup of Alliance against Cancer","author":"Ciliberto","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2026.103221_bb0035","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2025-099134","article-title":"Impact of comprehensive genomic profiling and molecular tumour board on costs and access to tailored therapies: real-world observational study","volume":"15","author":"De Micheli","year":"2025","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103221_bb0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41416-019-0489-3","article-title":"Molecular tumour boards and molecular diagnostics for patients with cancer in the Netherlands: experiences, challenges, and aspirations","volume":"121","author":"Willemsen","year":"2019","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.ctrv.2026.103221_bb0045","author":"Russo","year":"2025","journal-title":"Challenges and barriers of Molecular Tumor Boards implementation in European health systems: a scoping review"},{"key":"10.1016\/j.ctrv.2026.103221_bb0050","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ctrv.2026.103221_bb0055","doi-asserted-by":"crossref","DOI":"10.1186\/s12961-018-0320-2","article-title":"The GRADE evidence to decision (EtD) framework for health system and public health decisions","volume":"16","author":"Moberg","year":"2018","journal-title":"Health Res Policy Syst"},{"key":"10.1016\/j.ctrv.2026.103221_bb0060","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.jtho.2025.07.009","article-title":"Molecular tumor boards: a consensus statement from the International Association for the Study of Lung Cancer","volume":"20","author":"Aldea","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0065","first-page":"42","article-title":"Precision oncology implementation in a regional-based health care system: a professional consensus to define the pathway","author":"Barducci","year":"2024","journal-title":"J Cancer Policy"},{"key":"10.1016\/j.ctrv.2026.103221_bb0070","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.annonc.2023.06.011","article-title":"ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe","volume":"34","author":"Bayle","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0075","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1111\/1467-9566.12970","article-title":"Genomic expertise in action: molecular tumour boards and decision-making in precision oncology","volume":"41","author":"Bourret","year":"2019","journal-title":"Sociol Health Illn"},{"key":"10.1016\/j.ctrv.2026.103221_bb0080","first-page":"222","article-title":"A decalogue of molecular tumor board (MTB) recommendations from the CAN.HEAL consortium","author":"Ciliberto","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103221_bb0085","first-page":"14","article-title":"Challenges and obstacles in applying Therapeutical indications formulated in molecular tumor boards","author":"Crimini","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103221_bb0090","first-page":"6","article-title":"Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of molecular tumor boards","author":"Danesi","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103221_bb0095","first-page":"38","article-title":"Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer. The lancet regional health","author":"de Jager","year":"2024","journal-title":"Europe"},{"key":"10.1016\/j.ctrv.2026.103221_bb0100","first-page":"14","article-title":"Real-world data from a molecular tumor board-assisted Cancer care from a single Center in the Czech Republic: is precision oncology an accessible option, or a privilege for a minority of patients?","author":"Eid","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.ctrv.2026.103221_bb0105","first-page":"6","article-title":"Impact of a clinical genomics program on trial accrual for targeted treatments: practical approach overcoming barriers to accrual for underserved patients. JCO Clin","author":"Farhangfar","year":"2022","journal-title":"Cancer Informat"},{"key":"10.1016\/j.ctrv.2026.103221_bb0110","doi-asserted-by":"crossref","first-page":"E324","DOI":"10.1093\/oncolo\/oyad020","article-title":"Implementation of precision oncology in clinical practice: results of a National Survey for health care professionals","volume":"28","author":"Fasola","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2026.103221_bb0115","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41416-022-01922-3","article-title":"Patient attrition in molecular tumour boards: a systematic review","volume":"127","author":"Frost","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2026.103221_bb0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13040609","article-title":"Making the Most of complexity to create opportunities: comprehensive genomic profiling and molecular tumor Board for Patients with non-small cell lung Cancer (NSCLC)","volume":"13","author":"Fumagalli","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103221_bb0125","first-page":"9","article-title":"Systematic review and meta-analysis of molecular tumor board data on clinical effectiveness and evaluation gaps. NPJ precis","author":"Gladstone","year":"2025","journal-title":"Oncol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0130","first-page":"950","article-title":"Finding options beyond standard of Care in Oncology: a proposal for workflows utilizing knowledge databases","volume":"264","author":"Glocker","year":"2019","journal-title":"Stud Health Technol Inform"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103221_bb0135","article-title":"Real-world experience of molecular tumour boards for clinical decision-making for cancer patients. Npj precision","volume":"9","author":"Herrero Colomina","year":"2025","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2026.103221_bb0140","first-page":"48","article-title":"Supporting molecular tumor boards in molecular-guided decision-making \u2013 the current status of five German university hospitals","volume":"236","author":"Hinderer","year":"2017","journal-title":"Stud Health Technol Inform"},{"key":"10.1016\/j.ctrv.2026.103221_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13051151","article-title":"Transitioning the molecular tumor board from proof of concept to clinical routine: a German single-center analysis","volume":"13","author":"Hoefflin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103221_bb0150","doi-asserted-by":"crossref","DOI":"10.1111\/1467-9566.70040","article-title":"The role of algorithms in molecular tumour boards\u2014managing the gap between research and Clinic in Precision Medicine","volume":"47","author":"Hofmann","year":"2025","journal-title":"Sociol Health Illn"},{"key":"10.1016\/j.ctrv.2026.103221_bb0155","first-page":"24","article-title":"The role of molecular tumor boards in neuro-oncology: a nationwide survey","author":"H\u00f6nikl","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2026.103221_bb0160","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/gcc.22987","article-title":"Assigning evidence to actionability: an introduction to variant interpretation in precision cancer medicine","volume":"61","author":"Horak","year":"2022","journal-title":"Genes Chromosom Cancer"},{"key":"10.1016\/j.ctrv.2026.103221_bb0165","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1177\/03008916211062266","article-title":"The molecular tumor board: a tool for the governance of precision oncology in the real world","volume":"108","author":"Incorvaia","year":"2022","journal-title":"Tumori"},{"key":"10.1016\/j.ctrv.2026.103221_bb0170","first-page":"15","article-title":"Role of the molecular tumor Board for the Personalized Treatment of patients with metastatic breast Cancer: a focus on the state of the art in Italy","author":"Irelli","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103221_bb0175","doi-asserted-by":"crossref","first-page":"e1347","DOI":"10.1002\/onco.13580","article-title":"Multicenter comparison of molecular tumor boards in the Netherlands: definition, composition, methods, and targeted therapy recommendations","volume":"26","author":"Koopman","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2026.103221_bb0180","first-page":"2","article-title":"Challenges and solutions to system-wide use of precision oncology as the standard of care paradigm","author":"Lajmi","year":"2024","journal-title":"Cambridge Prisms Precision Medicine"},{"key":"10.1016\/j.ctrv.2026.103221_bb0185","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.trecan.2020.05.008","article-title":"Molecular tumor boards in clinical practice","volume":"6","author":"Luchini","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ctrv.2026.103221_bb0190","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.3390\/cancers14205040","article-title":"Identification of disparities in personalized Cancer care\u2014a joint approach of the German WERA consortium","volume":"14","author":"L\u00fcke","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103221_bb0195","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11523-024-01109-1","article-title":"Unveiling the digital evolution of molecular tumor boards","volume":"20","author":"Lutz","year":"2025","journal-title":"Target Oncol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0200","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1200\/EDBK_200759","article-title":"Art and challenges of precision medicine: interpreting and integrating genomic data into clinical practice","volume":"38","author":"Madhavan","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ctrv.2026.103221_bb0205","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bioe.12464","article-title":"Trust and responsibility in molecular tumour boards","volume":"32","author":"Merry","year":"2018","journal-title":"Bioethics"},{"key":"10.1016\/j.ctrv.2026.103221_bb0210","first-page":"4","article-title":"Prospective analysis of 895 patients on a UK genomics review board","author":"Moore","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103221_bb0215","first-page":"13","article-title":"HOPE (SOLTI-1903) breast cancer study: real-world, patient-centric, clinical practice study to assess the impact of genomic data on next treatment decision-choice in patients with locally advanced or metastatic breast cancer. Front","author":"Olivera-Salguero","year":"2023","journal-title":"Oncol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0220","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/gim.2016.174","article-title":"The cost of molecular-guided therapy in oncology: a prospective cost study alongside the MOSCATO trial","volume":"19","author":"Pag\u00e8s","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.ctrv.2026.103221_bb0225","first-page":"199","article-title":"Unlocking the potential of molecular tumor boards: from cutting-edge data interpretation to innovative clinical pathways","author":"Past\u00f2","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0230","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1177\/1078155219896395","article-title":"Current state assessment survey of challenges of pharmacogenomics within oncology pharmacy practice","volume":"26","author":"Przybylski","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.ctrv.2026.103221_bb0235","first-page":"3","article-title":"Precision oncology: separating the wheat from the chaff","author":"Remon","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103221_bb0240","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00428-023-03702-7","article-title":"Molecular diagnostics tailoring personalized cancer therapy-an oncologist\u2019s view","volume":"484","author":"Riedl","year":"2024","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ctrv.2026.103221_bb0245","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s11523-025-01160-6","article-title":"Streamlining and accelerating the molecular tumor board process at the university medical center Hamburg-Eppendorf","volume":"20","author":"Riemann","year":"2025","journal-title":"Target Oncol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0250","first-page":"169","article-title":"The challenge of the molecular tumor board empowerment in clinical oncology practice: a position paper on behalf of the AIOM- SIAPEC\/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian scientific societies","author":"Russo","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0255","first-page":"25","article-title":"Empowering personalized oncology: evolution of digital support and visualization tools for molecular tumor boards","author":"Strantz","year":"2025","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.ctrv.2026.103221_bb0260","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41591-022-01777-4","article-title":"A national precision cancer medicine implementation initiative for Norway","volume":"28","author":"Task\u00e9n","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103221_bb0265","first-page":"11","article-title":"The molecular tumor board as a step in cancer patient management: a southern Italian experience","author":"Tommasi","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ctrv.2026.103221_bb0270","first-page":"4","article-title":"Advancing molecular tumour boards: highly needed to maximise the impact of precision medicine","author":"Van De Haar","year":"2019","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103221_bb0275","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1093\/annonc\/mdx528","article-title":"Molecular tumor boards: current practice and future needs","volume":"28","author":"van der Velden","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0280","first-page":"7","article-title":"Molecular tumor board as a clinical tool for converting molecular data into real-world patient care. JCO precis","author":"Vingiani","year":"2023","journal-title":"Oncol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0285","first-page":"9","article-title":"A nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer. NPJ precis","author":"Volders","year":"2025","journal-title":"Oncol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0290","first-page":"30","article-title":"The molecular tumor board turns 10: the age of complexity","author":"Wahida","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2026.103221_bb0295","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1038\/s41591-025-03715-6","article-title":"Feasibility of multiomics tumor profiling for guiding treatment of melanoma","volume":"31","author":"Miglino","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103221_bb0300","first-page":"221","article-title":"Extension of the cBioPortal system to include a site-centered clinical trial search at the university hospital Schleswig-Holstein","volume":"331","author":"Neumann","year":"2025","journal-title":"Stud Health Technol Inform"},{"key":"10.1016\/j.ctrv.2026.103221_bb0305","doi-asserted-by":"crossref","DOI":"10.1200\/PO-24-00387","article-title":"Real-world outcomes of molecular tumor board treatment recommendations","author":"Nichetti","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2026.1641281","article-title":"Molecular tumor board availability and organization in sarcoma referral centers in Italy: are we on the right track?","volume":"16","author":"Onesti","year":"2026","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0315","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000533902","article-title":"Reimbursement in the context of precision oncology approaches in metastatic breast Cancer: challenges and experiences","volume":"19","author":"Pixberg","year":"2024","journal-title":"Breast Care (Basel)"},{"key":"10.1016\/j.ctrv.2026.103221_bb0320","doi-asserted-by":"crossref","first-page":"16355","DOI":"10.1007\/s00432-023-05365-y","article-title":"Prevalence of mutations in common tumour types in northern England and comparable utility of national and international trial finders","volume":"149","author":"Rae","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0325","first-page":"51","article-title":"Implementation and use of whole exome sequencing for metastatic solid cancer","author":"R\u00e9da","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ctrv.2026.103221_bb0330","first-page":"2","article-title":"Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate","author":"Ree","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103221_bb0335","first-page":"20","article-title":"Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards","author":"Rieke","year":"2022","journal-title":"BMC Med"},{"key":"10.1016\/j.ctrv.2026.103221_bb0340","first-page":"220","article-title":"Precision oncology - guideline of the Austrian, German and Swiss societies for hematology and medical oncology","author":"Rieke","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103221_bb0345","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000489138","article-title":"Molecular Tumor Boards","volume":"13","author":"Rody","year":"2018","journal-title":"Breast Care"},{"key":"10.1016\/j.ctrv.2026.103221_bb0350","first-page":"7","article-title":"How to read a next-generation sequencing report-what oncologists need to know","author":"Schmid","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103221_bb0355","first-page":"18","article-title":"SwissMTB: establishing comprehensive molecular cancer diagnostics in Swiss clinics","author":"Singer","year":"2018","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.ctrv.2026.103221_bb0360","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/bib\/bbx143","article-title":"Bioinformatics for precision oncology","volume":"20","author":"Singer","year":"2019","journal-title":"Brief Bioinform"},{"key":"10.1016\/j.ctrv.2026.103221_bb0365","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11948-017-9880-8","article-title":"Molecular tumor boards: ethical issues in the new era of data medicine","volume":"24","author":"Stoekl\u00e9","year":"2018","journal-title":"Sci Eng Ethics"},{"key":"10.1016\/j.ctrv.2026.103221_bb0370","first-page":"512","article-title":"Advancing usability and decision support for molecular tumor boards: insights from PM4Onco\u2019s visual analytics workshop","volume":"327","author":"Strantz","year":"2025","journal-title":"Stud Health Technol Inform"},{"key":"10.1016\/j.ctrv.2026.103221_bb0375","first-page":"230","article-title":"Clinical relevance of next-generation sequencing in patients aged 60 years or younger with pancreatic cancer: a Nationwide prospective cohort study","author":"Strijk","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103221_bb0380","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12254-024-00989-3","article-title":"Molecular tumor board\u2014editorial","volume":"17","author":"Taghizadeh","year":"2024","journal-title":"Memo - Magazine of European Medical Oncology"},{"key":"10.1016\/j.ctrv.2026.103221_bb0385","first-page":"251","article-title":"The molecular tumor board portal supports clinical decisions and automated reporting for precision oncology","volume":"3","author":"Tamborero","year":"2022","journal-title":"Nat Can"},{"key":"10.1016\/j.ctrv.2026.103221_bb0390","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/s41591-020-0969-2","article-title":"Support systems to guide clinical decision-making in precision oncology: the Cancer Core Europe molecular tumor board portal","volume":"26","author":"Tamborero","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103221_bb0395","first-page":"15","article-title":"Determinants affecting the clinical implementation of a molecularly informed molecular tumor board recommendation: experience from a tertiary Cancer center","author":"T\u00f6gel","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctrv.2026.103221_bb0400","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2340\/1651-226X.2024.39918","article-title":"Application of comprehensive molecular genetic profiling in precision cancer medicine","volume":"63","author":"T\u00f3th","year":"2024","journal-title":"Hungarian experiences Acta Oncol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmorw.2025.100679","article-title":"How to bring generative AI to oncology practice","volume":"11","author":"Truhn","year":"2026","journal-title":"ESMO Real World Data and Digital Oncology"},{"key":"10.1016\/j.ctrv.2026.103221_bb0410","first-page":"35","article-title":"Molecular tumor board for gynecologic malignancies: the real-world experience from the Department for Gynecology and Gynecologic Oncology of Kliniken Essen-Mitte","author":"Tsibulak","year":"2025","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ctrv.2026.103221_bb0415","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s12254-022-00800-1","article-title":"Applicability of ESMO-MCBS and ESCAT for molecular tumor boards","volume":"15","author":"Wolff","year":"2022","journal-title":"Memo - Magazine of European Medical Oncology"},{"key":"10.1016\/j.ctrv.2026.103221_bb0420","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40487-025-00325-7","article-title":"The impact and performance of the molecular tumor board: three-year activity in precision medicine for treatment of patients with Cancer from the Marche region, in Italy","volume":"13","author":"Agostinelli","year":"2025","journal-title":"Oncol Ther"},{"key":"10.1016\/j.ctrv.2026.103221_bb0425","first-page":"11","article-title":"The role of the pathologist in the next-generation era of tumor molecular characterization","author":"Angerilli","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.ctrv.2026.103221_bb0430","first-page":"14","article-title":"Optimizing precision oncology: structural frameworks for local MTB integration and outcome assessment","author":"Antone","year":"2026","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.ctrv.2026.103221_bb0435","first-page":"5","article-title":"Feasibility of high-throughput sequencing in clinical routine cancer care: lessons from the cancer pilot project of the France genomic medicine 2025 plan","author":"Auzanneau","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103221_bb0440","doi-asserted-by":"crossref","unstructured":"Ballatore Z, Bozzi F, Cardea S, Savino FD, Migliore A, Tarantino V, et al. Molecular Tumour Board (MTB): From Standard Therapy to Precision Medicine. Journal of Clinical Medicine 2023, 12:6666. doi:https:\/\/doi.org\/10.3390\/JCM12206666.","DOI":"10.3390\/jcm12206666"},{"key":"10.1016\/j.ctrv.2026.103221_bb0445","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1136\/ijgc-2022-003425","article-title":"A fully virtual and nationwide molecular tumor board for gynecologic cancer patients: the virtual experience of the MITO cooperative group","volume":"32","author":"Bartoletti","year":"2022","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ctrv.2026.103221_bb0450","first-page":"3","article-title":"Relevance of a molecular tumour board (MTB) for patients\u2019 enrolment in clinical trials: experience of the Institut curie","author":"Basse","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103221_bb0455","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/PO.20.00023","article-title":"Tumor molecular profiling: pediatric results of the ProfiLER study","author":"Benezech","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0460","doi-asserted-by":"crossref","DOI":"10.1186\/s13073-021-00897-9","article-title":"Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial","volume":"13","author":"Bertucci","year":"2021","journal-title":"Genome Med"},{"key":"10.1016\/j.ctrv.2026.103221_bb0465","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s12254-024-00977-7","article-title":"The molecular tumor board\u2014a key element of precision oncology","volume":"17","author":"Boos","year":"2024","journal-title":"Memo - Magazine of European Medical Oncology"},{"key":"10.1016\/j.ctrv.2026.103221_bb0470","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1007\/s10147-020-01661-6","article-title":"Implementation of a molecular tumor board at a regional level to improve access to targeted therapy","volume":"25","author":"Bourien","year":"2020","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0475","first-page":"1784519","article-title":"Advancing the adoption of oncology decision support tools in Europe: insights from CAN.HEAL. Front digit","volume":"8","author":"Frederickx","year":"2026","journal-title":"Health"},{"key":"10.1016\/j.ctrv.2026.103221_bb0480","first-page":"9","article-title":"A prospective pragmatic evaluation of automatic trial matching tools in a molecular tumor board. NPJ precis","author":"Gueguen","year":"2025","journal-title":"Oncol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0485","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cancergen.2026.04.001","article-title":"Optimized precision oncology through implementation of a comprehensive molecular analysis pipeline \u2013 relevance for additional therapeutic options","volume":"304\u2013305","author":"Harb","year":"2026","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.ctrv.2026.103221_bb0490","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jmoldx.2025.06.006","article-title":"Microcosting study of genomic profiling for precision Cancer medicine: application from the National Infrastructure for precision diagnostics in Norway","volume":"27","author":"Henkel","year":"2025","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.ctrv.2026.103221_bb0495","first-page":"1659","article-title":"Modelling and implementation of a precision-oncology data-integration platform for real-word molecular tumor Borad decision-making","volume":"336","author":"Hern\u00e1ndez-P\u00e9rez","year":"2026","journal-title":"Stud Health Technol Inform"},{"key":"10.1016\/j.ctrv.2026.103221_bb0500","doi-asserted-by":"crossref","unstructured":"H\u00f6nikl LS, Lange S, Meyer B, Combs SE, L\u00f6rsch AM, Illert AL, et al. Current landscape and challenges of neuro-oncological molecular tumor boards in Germany: results of a nationwide follow-up survey. J Neuro-Oncol 2026;177:82-. doi:https:\/\/doi.org\/10.1007\/S11060-026-05549-9\/FIGURES\/1.","DOI":"10.1007\/s11060-026-05549-9"},{"key":"10.1016\/j.ctrv.2026.103221_bb0505","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/ijc.30828","article-title":"Precision oncology based on omics data: the NCT Heidelberg experience","volume":"141","author":"Horak","year":"2017","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2026.103221_bb0510","first-page":"6","article-title":"MTPpilot: an interactive software for visualization of next-generation sequencing results in molecular tumor boards. JCO Clin","author":"Kahraman","year":"2022","journal-title":"Cancer Informat"},{"key":"10.1016\/j.ctrv.2026.103221_bb0515","first-page":"10","article-title":"Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board","author":"Krieghoff-Henning","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103221_bb0520","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/0284186X.2023.2185542","article-title":"Feasibility and early clinical impact of precision medicine for late-stage cancer patients in a regional public academic hospital","volume":"62","author":"Ladekarl","year":"2023","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0525","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejca.2019.12.017","article-title":"Support of a molecular tumour board by an evidence-based decision management system for precision oncology","volume":"127","author":"Lamping","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2026.103221_bb0530","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/bjc.2014.211","article-title":"Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial","volume":"111","author":"Le Tourneau","year":"2014","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103221_bb0535","article-title":"The role of the molecular tumor board: learnings from the ROME trial. Npj precision","volume":"10","author":"Marchetti","year":"2026","journal-title":"Oncology"},{"key":"10.1016\/j.ctrv.2026.103221_bb0540","first-page":"3","article-title":"Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer","author":"Rolfo","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2026.103221_bb0545","unstructured":"Molecular Tumor Board: Charit\u00e9 Comprehensive Cancer Center - Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin 2026 https:\/\/cccc.charite.de\/en\/information_for_medical_professionals\/platform_for_personalized_cancer_medicine\/molecular_tumor_board\/ (accessed October 2, 2026)."},{"key":"10.1016\/j.ctrv.2026.103221_bb0550","unstructured":"Molecular Tumor Board \u2013 MTB \u2013 Ricerca IFO 2026 https:\/\/ricerca.ifo.it\/ire-research\/ire-excellences\/molecular-tumor-board-mtb\/ (accessed October 2, 2026)."},{"key":"10.1016\/j.ctrv.2026.103221_bb0555","unstructured":"Molecular Tumor Board | IRCCS - Istituto Nazionale dei Tumori 2026 https:\/\/www.istitutotumori.mi.it\/molecular-tumor-board-0 (accessed October 2, 2026)."},{"key":"10.1016\/j.ctrv.2026.103221_bb0560","first-page":"17","article-title":"Development and validation of ACTE-MTB: a tool to systematically assess the maturity of molecular tumor boards","author":"Love","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2026.103221_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/j.hlpt.2026.101287","article-title":"Building consensus for molecular tumor board implementation in Europe: a Delphi procedure","volume":"15","author":"Russo","year":"2026","journal-title":"Health Policy Technol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0570","first-page":"4","article-title":"Implementation of health technology: directions for research and practice. Front digit","author":"van Gemert-Pijnen","year":"2022","journal-title":"Health"},{"key":"10.1016\/j.ctrv.2026.103221_bb0575","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1093\/jncimonographs\/lgs004","article-title":"Implementation and spread of interventions into the multilevel context of routine practice and policy: implications for the Cancer care continuum","volume":"2012","author":"Yano","year":"2012","journal-title":"J Natl Cancer Inst Monogr"},{"key":"10.1016\/j.ctrv.2026.103221_bb0580","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaoncol.2022.6296","article-title":"Adoption of innovative therapies across oncology practices-evidence from immunotherapy","volume":"9","author":"Carroll","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0585","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/joim.13698","article-title":"Implementation of precision medicine in healthcare-a European perspective","volume":"294","author":"Stenzinger","year":"2023","journal-title":"J Intern Med"},{"key":"10.1016\/j.ctrv.2026.103221_bb0590","first-page":"50","article-title":"PFMG2025-integrating genomic medicine into the national healthcare system in France. The lancet regional health","author":"Abadie","year":"2025","journal-title":"Europe"},{"issue":"190","key":"10.1016\/j.ctrv.2026.103221_bb0595","first-page":"30","article-title":"Istituzione dei Molecular tumor board e individuazione dei centri specialistici per l\u2019esecuzione dei test per la profilazione genomica estesa Next generation sequencing (NGS): Decreto 30 maggio 2023","volume":"164","author":"Ministero della Salute","year":"2023","journal-title":"Gazzetta Ufficiale della Repubblica Italiana"},{"key":"10.1016\/j.ctrv.2026.103221_bb0600","year":"2026"},{"key":"10.1016\/j.ctrv.2026.103221_bb0605","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/oncolo\/oyac069","article-title":"Developing a virtual equity hub: adapting the tumor board model for equity in Cancer care","volume":"27","author":"Irwin","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2026.103221_bb0610","article-title":"The impact of the multi-disciplinary molecular tumour board and integrative next generation sequencing on clinical outcomes in advanced solid tumours","volume":"36","author":"El Helali","year":"2023","journal-title":"Lancet Reg Health West Pac"},{"key":"10.1016\/j.ctrv.2026.103221_bb0615","first-page":"15","article-title":"Clinical implementation of next-generation sequencing testing and genomically-matched therapy: a real-world data in a tertiary hospital","author":"Kim","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.ctrv.2026.103221_bb0620","article-title":"Cancer care and outreach in the south Asian Association for Regional Cooperation (SAARC) region: overcoming barriers and addressing challenges","volume":"25","author":"Huq","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2026.103221_bb0625","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/cas.14754","article-title":"Establishment and implementation of Cancer genomic medicine in Japan","volume":"112","author":"Mukai","year":"2021","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2026.103221_bb0630","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1200\/OP-25-00144","article-title":"Where have we been and where are we going? The state of the hematology and medical oncologist workforce in America","volume":"21","author":"Kirkwood","year":"2025","journal-title":"JCO Oncol Pract"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001350?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226001350?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:29:51Z","timestamp":1793316591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226001350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":126,"alternative-id":["S0305737226001350"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103221","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular tumor boards implementation in Europe: a scoping review and thematic analysis of challenges and facilitators","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103221","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103221"}}